Efficacy of 1st-line therapy in patients with locally advanced and metastatic esophageal cancer

Introduction. Currently, there is no consensus regarding the optimal 1st-line chemotherapy regimen for patients with locally advanced and disseminated esophageal squamous cell carcinoma. Aim. To improve treatment outcomes in patients with locally advanced and metastatic esophageal squamous cell carcinoma by optimizing first-line systemic antitumor drug therapy regimens. Materials and methods. A retrospective analysis of treatment outcomes was conducted for 271 patients with locally advanced and disseminated forms of esophageal squamous cell carcinoma. The patients received treatment with either two-drug (paclitaxel + cisplatin (TP) and paclitaxel + carboplatin (TC)) or a three-drug (docetaxel + cisplatin + 5-fluorouracil (mDCF)) combinations. The use of the three-drug mDCF combination is characterized by lower toxicity and a lower incidence of complications compared to the two-drug TP and TC regimens. Results. To date, despite their toxic effects, the investigated treatment regimens are considered safe and are most frequently prescribed for locally advanced and disseminated forms of esophageal squamous cell carcinoma. Conclusion. The modified 2-week mDCF chemotherapy regimen showed high efficacy and manageable toxicity as a 1st-line therapy for esophageal squamous cell carcinoma.

Authors

Institutions

Publication Details

Journal
Head and neck tumors (HNT)
Published
2026-11-20
DOI
https://doi.org/10.17650/2222-1468-2026-16-3-52-56
Primary Topic
Esophageal Cancer Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Efficacy of 1st-line therapy in patients with locally advanced and metastatic esophageal cancer

Victor V. Sokolovskiy
Head and neck tumors (HNT)
Esophageal Cancer Research and Treatment
article

Efficacy of 1st-line therapy in patients with locally advanced and metastatic esophageal cancer

Victor V. Sokolovskiy
article en

Abstract

Introduction. Currently, there is no consensus regarding the optimal 1st-line chemotherapy regimen for patients with locally advanced and disseminated esophageal squamous cell carcinoma. Aim. To improve treatment outcomes in patients with locally advanced and metastatic esophageal squamous cell carcinoma by optimizing first-line systemic antitumor drug therapy regimens. Materials and methods. A retrospective analysis of treatment outcomes was conducted for 271 patients with locally advanced and disseminated forms of esophageal squamous cell carcinoma. The patients received treatment with either two-drug (paclitaxel + cisplatin (TP) and paclitaxel + carboplatin (TC)) or a three-drug (docetaxel + cisplatin + 5-fluorouracil (mDCF)) combinations. The use of the three-drug mDCF combination is characterized by lower toxicity and a lower incidence of complications compared to the two-drug TP and TC regimens. Results. To date, despite their toxic effects, the investigated treatment regimens are considered safe and are most frequently prescribed for locally advanced and disseminated forms of esophageal squamous cell carcinoma. Conclusion. The modified 2-week mDCF chemotherapy regimen showed high efficacy and manageable toxicity as a 1st-line therapy for esophageal squamous cell carcinoma.

Head and neck tumors (HNT)Vol. 16(3)
Sechenov University (RU), Ministry of Health of the Russian Federation (RU)
Esophageal Cancer Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon